New targeted therapy for liver cancer
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma
This study is testing a new treatment for liver cancer that uses tiny particles to deliver special medicines directly to the cancer cells, hoping to make the treatment work better and help patients live longer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-10754229 on NIH RePORTER |
What this research studies
This research investigates a novel therapy for hepatocellular carcinoma (HCC), a common and deadly liver cancer. It focuses on two oncogenes, AEG-1 and MDA-9, which are involved in the development and progression of HCC. The researchers have developed a targeted delivery system using nanoplexes to deliver AEG-1 siRNA and a small molecule inhibitor for MDA-9, aiming to reduce cancer cell invasion and improve treatment outcomes. The approach combines these therapies with an existing FDA-approved drug to enhance effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced hepatocellular carcinoma who have limited treatment options.
Not a fit: Patients with early-stage liver cancer or those whose cancer is not related to the oncogenes being targeted may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with advanced liver cancer.
How similar studies have performed: Previous research has shown promise in targeting similar oncogenes in cancer therapies, indicating potential for success with this novel approach.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Sarkar, Devanand — Virginia Commonwealth University
- Study coordinator: Sarkar, Devanand
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.